67401-65-4

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-(methoxycarbonylamino)-3-phenylpropanoic acid is used as a building block for the synthesis of various biologically active compounds due to its unique structural features and functional groups. Its presence in the pharmaceutical industry is attributed to its potential role in creating new drugs or enhancing the efficacy of existing ones.
Used in Drug Synthesis:
In the field of drug synthesis, (R)-2-(methoxycarbonylamino)-3-phenylpropanoic acid is utilized as a key component in the development of novel pharmaceuticals. Its structural versatility and the presence of functional groups make it a valuable asset for designing and synthesizing new drugs with improved properties and targeted applications.
Further research and characterization of (R)-2-(methoxycarbonylamino)-3-phenylpropanoic acid are essential to fully understand its potential uses and properties, which could lead to breakthroughs in the pharmaceutical and drug synthesis industries.

Upstream product

• 673-06-3 D-(R)-phenylalanine 
• 79-22-1 methyl chloroformate 
• 1243-60-3 N-methoxycarbonyl-D-phenylalanine-p-nitrophenyl ester 
• 70148-11-7 N-Methoxycarbonylphenylalanin-p-nitrophenylester 

Downstream Products

• 166742-96-7 (R)-N-methoxy-2-(methoxycarbonylamino)-3-phenylpropanamide 
• 166742-75-2 (R)-1,2,3,4-tetrahydro-N-methyl-3-quinolinamine 
• 256397-63-4 (R)-(5-amino-2,3-dihydro-1H-inden-2-yl)carbamic acid methyl ester 
• 100160-67-6 ((R)-1-Chlorocarbonyl-2-phenyl-ethyl)-carbamic acid methyl ester 

Relevant academic research and scientific papers

HPTP-BETA INHIBITORS

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility ar

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.